SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-413866"
 

Search: onr:"swepub:oai:DiVA.org:uu-413866" > Survival following ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Gowin, KrisstinaUniv Arizona, Div Hematol & Oncol, 3838 N Campbell Ave, Tucson, AZ 85719 USA. (author)

Survival following allogeneic transplant in patients with myelofibrosis

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-05-08
  • AMER SOC HEMATOLOGY,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-413866
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-413866URI
  • https://doi.org/10.1182/bloodadvances.2019001084DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143677860URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ballen, KarenUniv Virginia Hlth Syst, Div Hematol & Oncol, Charlottesville, VA USA. (author)
  • Ahn, Kwang WooMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Hu, Zhen-HuanMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Ali, HarisCity Hope Natl Med Ctr, Duarte, CA USA. (author)
  • Arcasoy, Murat O.Duke Univ, Sch Med, Dept Med, Div Hematol, Durham, NC 27706 USA. (author)
  • Devlin, RebeccaUniv Hlth Network, Toronto, ON, Canada. (author)
  • Coakley, MariaInst Canc Res, London, England. (author)
  • Gerds, Aaron T.Cleveland Clin, Taussig Canc Inst, Hematol & Med Oncol, Cleveland, OH 44106 USA. (author)
  • Green, MichaelDuke Univ, Sch Med, Dept Med, Div Hematol, Durham, NC 27706 USA. (author)
  • Gupta, VikasUniv Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada. (author)
  • Hobbs, GabrielaMassachusetts Gen Hosp, Boston, MA 02114 USA. (author)
  • Jain, TaniaMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. (author)
  • Kandarpa, MalathiUniv Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. (author)
  • Komrokji, RamiH Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. (author)
  • Kuykendall, Andrew T.H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. (author)
  • Luber, KierstinWashington Univ, Sch Med, Dept Osteopath Med, St Louis, MO USA. (author)
  • Masarova, LuciaMD Anderson Canc Ctr, Houston, TX USA. (author)
  • Michaelis, Laura C.Med Coll Wisconsin, Hematol & Med Oncol, Milwaukee, WI 53226 USA. (author)
  • Patches, SarahDana Farber Canc Inst, Boston, MA 02115 USA. (author)
  • Pariser, Ashley C.Northwestern Mem Hosp, Chicago, IL 60611 USA. (author)
  • Rampal, RaajitMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. (author)
  • Stein, BradyNorthwestern Mem Hosp, Chicago, IL 60611 USA. (author)
  • Talpaz, MosheMD Anderson Canc Ctr, Houston, TX USA. (author)
  • Verstovsek, SrdanMD Anderson Canc Ctr, Houston, TX USA. (author)
  • Wadleigh, MarthaDana Farber Canc Inst, Boston, MA 02115 USA. (author)
  • Agrawal, VaibhavIndiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA. (author)
  • Aljurf, MahmoudKing Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. (author)
  • Angel Diaz, MiguelHosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain. (author)
  • Avalos, Belinda R.Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Atrium Hlth, Charlotte, NC USA. (author)
  • Bacher, UlrikeUniv Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland. (author)
  • Bashey, AsadNorthside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. (author)
  • Beitinjaneh, Amer M.Univ Miami, Dept Med, Miami, FL USA. (author)
  • Cerny, JanUniv Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA. (author)
  • Chhabra, SaurabhMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Copelan, EdwardCarolinas HealthCare Syst, Levine Canc Inst, Atrium Hlth, Charlotte, NC USA. (author)
  • Cutler, Corey S.Dana Farber Canc Inst, Dept Med Oncol, Div Transplantat & Cellular Therapy, Boston, MA 02115 USA. (author)
  • DeFilipp, ZachariahMassachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA. (author)
  • Gadalla, Shahinaz M.NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA. (author)
  • Ganguly, SiddharthaUniv Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA. (author)
  • Grunwald, Michael R.Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Atrium Hlth, Charlotte, NC USA. (author)
  • Hashmi, Shahrukh K.King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.;Mayo Clin, Dept Internal Med, Rochester, MN USA. (author)
  • Kharfan-Dabaja, Mohamed A.Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL 32224 USA. (author)
  • Kindwall-Keller, TamilaUniv Virginia Hlth Syst, Div Hematol & Oncol, Charlottesville, VA USA. (author)
  • Kroeger, NicolausUniv Hosp Hamburg, Dept Stem Cell Transplantat, Hamburg, Germany. (author)
  • Lazarus, Hillard M.Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. (author)
  • Liesveld, Jane L.Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. (author)
  • Litzow, Mark R.Mayo Clin Rochester, Div Hematol, Rochester, MN USA.;Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA. (author)
  • Marks, David, IUniv Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England. (author)
  • Nathan, SunitaRush Univ, Med Ctr, Chicago, IL 60612 USA. (author)
  • Nishihori, TaigaH Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (author)
  • Olsson, RichardUppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden(Swepub:uu)riols677 (author)
  • Pawarode, AttapholUniv Michigan, Sch Med, Dept Internal Med, Blood & Marrow Transplantat Program,Div Hematol O, Ann Arbor, MI USA. (author)
  • Rowe, Jacob M.Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel. (author)
  • Savani, Bipin N.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. (author)
  • Savoie, Mary LynnTom Baker Canc Clin, Calgary, AB, Canada. (author)
  • Seo, SachikoDokkyo Med Univ, Dept Haematol & Oncol, Mibu, Tochigi, Japan. (author)
  • Solh, MelhemNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA. (author)
  • Tamari, RoniMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. (author)
  • Verdonck, Leo F.Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands. (author)
  • Yared, Jean A.Univ Maryland, Greenebaum Comprehens Canc Ctr, Dept Med, Div Hematol Oncol,Blood Marrow Transplantat Progr, Baltimore, MD 21201 USA. (author)
  • Alyea, EdwinDana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA. (author)
  • Popat, UdayMD Anderson Canc Ctr, Houston, TX USA. (author)
  • Sobecks, RonaldCleveland Clin, Cleveland, OH 44106 USA. (author)
  • Scott, Bart L.Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. (author)
  • Nakamura, RyotaroCity Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA. (author)
  • Mesa, RubenUT Hlth San Antonio MD Anderson, San Antonio, TX USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Univ Arizona, Div Hematol & Oncol, 3838 N Campbell Ave, Tucson, AZ 85719 USA.Univ Virginia Hlth Syst, Div Hematol & Oncol, Charlottesville, VA USA. (creator_code:org_t)

Related titles

  • In:Blood Advances: AMER SOC HEMATOLOGY4:9, s. 1965-19732473-95292473-9537

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view